Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.944722
Keywords
Beta-2-microglobulin (beta 2M); major histocompatibility complex (MHC) class I; T cells; melanoma; immunotherapy
Categories
Funding
- National Natural Science Foundation of China
- Program of Science and Technology Innovation Action of Science and Technology Commission of Shanghai Municipality
- Scientific research project of Shanghai Municipal Health Commission
- Interdisciplinary research joint fund project of Tongji University
- [81770934]
- [22Y11910100]
- [202140416]
- [2022-4-ZD-09]
Ask authors/readers for more resources
This review discusses the role and impact of the B2M gene in melanoma immunity, as well as its potential in melanoma treatment.
Despite the remarkable success of immunotherapy in the treatment of melanoma, resistance to these agents still affects patient prognosis and response to therapies. Beta-2-microglobulin (beta 2M), an important subunit of major histocompatibility complex (MHC) class I, has important biological functions and roles in tumor immunity. In recent years, increasing studies have shown that B2M gene deficiency can inhibit MHC class I antigen presentation and lead to cancer immune evasion by affecting beta 2M expression. Based on this, B2M gene defect and T cell-based immunotherapy can interact to affect the efficacy of melanoma treatment. Taking into account the many recent advances in B2M-related melanoma immunity, here we discuss the immune function of the B2M gene in tumors, its common genetic alteration in melanoma, and its impact on and related improvements in melanoma immunotherapy. Our comprehensive review of beta 2M biology and its role in tumor immunotherapy contributes to understanding the potential of B2M gene as a promising melanoma therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available